RecruitingNot ApplicableNCT07196462

Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia


Sponsor

Vanderbilt University Medical Center

Enrollment

100 participants

Start Date

Jan 15, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The central hypothesis is this: Brain circuits most relevant to cannabis use in schizophrenia are distinct from pathways identified in healthy controls who use cannabis. This study seeks to provide evidence that targeted stimulation of the DMN leads to both altered network activity and a concomitant behavioral change in cue-induced craving and cognitive performance in individuals with schizophrenia and schizoaffective disorder, while targeted stimulation of the L DLPFC leads to these changes in healthy controls who use cannabis. This study will test a model that integrates brain network pathophysiology and cognition to 1) explain the prevalence of cannabis use in schizophrenia and 2) identify a target for engagement in schizophrenia. This study seeks to establish a neuroscientific framework to guide future treatment-oriented studies aimed at reducing craving and improving cognitive performance in individuals with schizophrenia and schizoaffective disorder. This is a study of the effect of 2 rTMS interventions on functional connectivity and craving in individuals with schizophrenia or schizoaffective disorder and healthy controls who use cannabis. Aim 1: Target Engagement: Determine if rTMS manipulates functional connectivity of each target (DMN, L DLPFC) (n=100). Aim 2: Clinical Efficacy: Determine if rTMS affects cue-induced craving and if craving change correlates with change in functional connectivity (n=100). As an exploratory analysis, the factors that explain individual variance in rTMS-induced connectivity change will also be explored.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a type of targeted brain stimulation (using magnetic pulses) can reduce cannabis cravings in people who have a psychotic disorder like schizophrenia and currently use cannabis. Researchers also want to understand how the brain responds to this treatment. **You may be eligible if...** - You are 18–65 years old - You have been diagnosed with a psychotic disorder (or are a healthy volunteer without one) - You currently use cannabis and are willing to confirm this with a urine test - You are in stable outpatient psychiatric care with no hospitalizations or medication changes in the past 30 days - You can read, speak, and understand English **You may NOT be eligible if...** - You have a history of seizures or epilepsy - You have metal implants in your head or skull - You have a pacemaker or similar implanted device - You use substances other than cannabis or nicotine (e.g., cocaine, amphetamines) within the past 3 months - You have had a significant head injury with loss of consciousness - You are pregnant or planning to become pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICE3 Minute iTBS to the L DLPFC

Five daily sessions of TMS (iTBS) to the L DLPFC target.

DEVICEOne-Minute, Personalized, DMN Targeted CTBS

Personalized, DMN Targeted CTBS to the DMN for one minute, five daily sessions.


Locations(1)

Vanderbilt Psychiatric Hospital

Nashville, Tennessee, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07196462


Related Trials